Rare disease drug developer Swedish Orphan Biovitrum AB (Sobi) has named Guido Oelkers as the company’s new President and CEO. Oelkers, who holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London, joins from BSN Medical GmbH, where he held the position of CEO.